Sidecar: Two-Year Telehealth Runway to 2027: Three Actionable Moves for Healthcare Investors

The U.S. Congress has extended Medicare telehealth coverage through 2027, changing the calculus for telehealth deals in several concrete ways. In this Sidecar, Healthcare Transactional Practice co-heads Markus Bolsinger and Jennifer Hutchens and associate Brooke Meadowcroft discuss the principles that will help investors act on the opportunities brought by this increased deal window while also building strategies to outlast any single policy.

In this Sidecar, Dechert partners Jarlath Pratt, Clemens York and Mike Okkonen break down the European Commission's proposed Industrial Accelerator Act and its implications for foreign direct investment in the EU's emerging strategic sectors, including batteries, solar, EVs, and critical raw materials. The draft IAA proposes a mandatory pre-closing notification regime with strict conditions, including ownership caps, joint venture requirements and technology transfer obligations, targeting investors from countries controlling more than 40% of global manufacturing capacity in the relevant sectors. Non-EU investors caught by the proposed new regime are well-advised to monitor related developments and to start considering partnerships with EU investors ahead of the legislation being finalized.

With buyout and exit values climbing, GPs are leaning in — despite shifting U.S. trade policy, European political stasis and geopolitical uncertainty. On Dechert’s Committed Capital, Everstone Group's Sujoy Bose, Investcorp’s Daniel Lopez-Cruz and Ridgemont Equity Partners’ Dan Harknett join Dechert’s Markus Bolsinger, Sabina Comis, Maria Tan Pedersen and Nick Tomlinson to discuss 2026 opportunities and the legal issues shaping PE dealmaking.Show NotesDechert's 2026 Global Private Equity Outlook

Will your next deal trigger a state “mini-HSR” (Hart-Scott-Rodino) filing? In this episode of Committed Capital Sidecar, Dechert partner James Fishkin unpacks the rise of state mini-HSR premerger filing laws under the Uniform Antitrust Premerger Notification Act – who must file, the key nexus thresholds and what materials must be submitted. He spotlights Washington and Colorado’s early adoption, outlines civil penalties for noncompliance and shares practical guidance for dealmakers on coordinating multi-state filings and managing state attorneys general review risk.

How will Medicare’s telehealth back-and-forth – and new developments like the 10-year CMS ACCESS Model – reshape the investor playbook? Markus Bolsinger, co-head of Dechert’s global private equity practice, joins Dechert partner Jennifer Hutchens and associate Brooke Meadowcroft to unpack shifts from pandemic-era expansion to the October 1, 2025 “telehealth cliff” and reinstatement through January 30, and what they mean for strategics and PE. They explore the convergence with DTC pharma and how digital-first infrastructure, data integration and safeguards can make telehealth the connective tissue between coverage and access to care.

How might Oregon’s new laws restricting private equity in healthcare operations affect regulations in other states, and what should investors and healthcare providers know about them? In the debut edition of Committed Capital’s PE Rx series examining the intersection of PE and healthcare, Dechert partners Markus Bolsinger and Jennifer Hutchens unpack the history and impact of Oregon’s SB 951 and HB 3410, including their practical implications for PE sponsors and management service organizations, the state’s evolving stance on the corporate practice of medicine and much more. Show Notes"Healthcare Private Equity Soon to Face Significant Hurdles in Oregon," Dechert OnPoint (June 10, 2025)"New Oregon Law Leads Nation in Restricting Healthcare Investment," Dechert OnPoint (June 26, 2025)

Earlier this month, a U.S. executive order was signed to broaden the availability of alternative asset investments for individuals with 401(k) plans. In this Sidecar episode of our Committed Capital podcast, Dechert partners Bill Bielefeld and Steve Rabitz dive into the challenges fiduciaries face under ERISA and the regulatory shifts poised to redefine retirement investment strategies moving forward. From liquidity concerns to fee structures and legal uncertainties, this comprehensive conversation sheds light on how plan sponsors and asset managers can navigate the evolving landscape of alternative asset inclusion in participant-directed retirement plans.Show Notes:New Order ‘Targets’ 401(k) Plan ‘Alternatives’: President Takes Aim at Legal Barriers and Litigation Risks, Dechert OnPoint (August 11, 2025)

Despite a year of geopolitical volatility and economic uncertainty, private equity demonstrated its resilience in 2024. With challenges still ahead, how are PE managers setting themselves up for success in the coming year? In this special episode, Dechert partners Sarah Kupferman, Rani Habash, Eliot Relles and Sam Whittaker share their perspectives and insights on key findings from Dechert’s 2025 Global Private Equity Outlook report, including the increased appetite for co-investments and club deals, the impact of regulatory changes and private credit’s growing role in bridging funding gaps. Show Notes 2025 Global Private Equity Outlook 

The FTC’s recent overhaul of its premerger notification requirements has culminated in a completely new HSR form, which recently became effective and now obligates parties to reportable transactions to disclose substantially more information to the antitrust agencies up front.  What impact will these new requirements have on private equity firms now that they are in effect? In this Sidecar episode, Dechert antitrust partner James Fishkin and counsel Beverly Ang highlight a few key changes in the new rules and how PE firms should adjust in order to ensure compliance with the new regime.Show Notes The New Hart-Scott-Rodino Reporting Requirements: A Roadmap for Filers, Dechert OnPoint (Oct. 30, 2024)

Private equity firms are increasingly looking at strategic options both for their business and fundraising, including GP-stake sales and seeding transactions. What factors do GPs consider when evaluating these options? In this episode, Dechert’s Sam Kay leads a discussion with Rede Partners’ Magnus Goodlad and New Catalyst Strategic Partners’ Demetrius Sidberry on how the market is developing, how businesses are valued, the different methodologies and investment structures for either a GP-stake sale or a seeding arrangement, and more.